13 studies found for:    Ampligen
Show Display Options
Rank Status Study
1 Recruiting Safety Study of FluMist With and Without Ampligen
Condition: Influenza, Human
Interventions: Drug: FluMist + Poly I:Poly C12U 50 ug;   Drug: FluMist + Poly I:Poly C12U 200 ug;   Drug: FluMist + Poly I:Poly C12U 500 ug;   Drug: FluMist + Poly I:Poly C12U 1250 ug;   Drug: FluMist + Placebo
2 Active, not recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
3 Completed The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
Conditions: HIV Seropositivity;   HIV Infection
Intervention: Drug: poly I-poly C12U
4 Terminated Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Conditions: HIV Seropositivity;   HIV Infection
Intervention: Drug: poly I-poly C12U
5 Recruiting Study of Ampligen in Chronic Fatigue Syndrome
Condition: Chronic Fatigue Syndrome
Intervention: Drug: Poly I: Poly C12U
6 Completed A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
Condition: HIV Infections
Interventions: Drug: Ampligen;   Drug: Zidovudine
7 Completed A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
Condition: HIV Infections
Intervention: Drug: Ampligen
8 Completed A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects
Condition: HIV Infections
Intervention: Drug: Ampligen
9 Completed A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection
Condition: HIV Infections
Intervention: Drug: Ampligen
10 Completed The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Ampligen
11 Recruiting αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface;   Malignant Peritoneal Mesothelioma;   Peritoneal Carcinomatosis
Interventions: Biological: DC vaccine;   Drug: Celecoxib;   Drug: Interferon Alfa-2b;   Biological: rintatolimod
12 Unknown  A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Biological: OC-L/Montanide ISA 51 VG;   Biological: Ampligen;   Biological: Prevnar
13 Recruiting Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Procedure: Surgical resection of recurrent colorectal cancer;   Drug: Chemokine-modulatory (CKM) regimen

Indicates status has not been verified in more than two years